HALOZYME THERAPEUTICS, INC. (HALO)
$0.00+$0.00 (+0.00%) TodayExtended Hours
Halozyme Therapeutics Inc is a biotechnology company focused on developing and commercializing novel oncology therapies. The company seeks to create therapies focused on human enzymes that alter tumors. Halozyme focuses on developing its proprietary products in therapeutic areas with a focus on oncology, and licensing its technology to biopharmaceutical companies to collaboratively develop products. ENHANZE drug delivery technology was introduced with the proprietary enzyme rHuPH20, to facilitate the subcutaneous delivery of injected drugs and fluids, with the goal of improving the patient experience with rapid SC delivery and reduced treatment burden. The company's operations are based in the United States, with minimal long-lived assets located internationally.
| Form 4 transaction type | Transactions | Shares | Total value |
|---|---|---|---|
| Open-market sale | 27 | 124,103 | $10.75M |
| Grant or award | 4 | 225,041 | |
| Option exercise | 20 | 268,522 | |
| Tax withholding / forfeiture | 2 | 8,123 |
Dollar totals are shown for open-market purchases and sales only. Grants, option exercises, gifts and tax withholding are reported by share count because they are not trades at a market price.
62 Form 4 filings on record, the earliest from Oct 9, 2024, newest first. Filing history page 3 of 3.
| Date | Insider | Transaction | Security | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Michael J. Labarre - Officer | Option exercise | Common Stock | 5,509 | $16.65 | $92K | |
| Michael J. Labarre - Officer | Option exercise | Common Stock | 4,491 | $19.98 | $90K | |
| Michael J. Labarre - Officer | Open-market sale | Common Stock | 9,923 | $53.74 | $533K | |
| Michael J. Labarre - Officer | Open-market sale | Common Stock | 77 | $54.25 | $4K | |
| Michael J. Labarre - Officer | Option exercise | Common Stock | 10,000 | $19.98 | $200K | |
| Michael J. Labarre - Officer | Open-market sale | Common Stock | 10,000 | $53.26 | $533K | |
| Michael J. Labarre - Officer | Option exercise | Option to Purchase Common Stock | 5,509 | $0.00 | - | |
| Michael J. Labarre - Officer | Option exercise | Option to Purchase Common Stock | 4,491 | $0.00 | - | |
| Michael J. Labarre - Officer | Option exercise | Option to Purchase Common Stock | 10,000 | $0.00 | - | |
| Helen Torley - Officer | Option exercise | Common Stock | 10,000 | $13.87 | $139K | |
| Helen Torley - Officer | Open-market sale | Common Stock | 9,100 | $53.94 | $491K | |
| Helen Torley - Officer | Open-market sale | Common Stock | 900 | $54.57 | $49K | |
| Helen Torley - Officer | Option exercise | Common Stock | 10,000 | $13.87 | $139K | |
| Helen Torley - Officer | Open-market sale | Common Stock | 5,981 | $51.85 | $310K | |
| Helen Torley - Officer | Open-market sale | Common Stock | 1,615 | $53.31 | $86K | |
| Helen Torley - Officer | Open-market sale | Common Stock | 2,404 | $53.91 | $130K | |
| Helen Torley - Officer | Option exercise | Option to Purchase Common Stock | 10,000 | $13.87 | $139K | |
| Helen Torley - Officer | Option exercise | Option to Purchase Common Stock | 10,000 | $13.87 | $139K |
This is as far as the anonymous view goes. Create a free account for all 62 HALO filings on record.
A Form 144 is notice of an INTENDED sale, not a completed one. It often precedes the Form 4 that reports the trade actually happening.
| Filed | Filer | Relationship | Shares | Market value | Notice |
|---|---|---|---|---|---|
| Helen Torley | President, CEO, Director | 240,000 | $23.68M | View on EDGAR | |
| CORTNEY A CAUDILL | Officer | 41,702 | $4.30M | View on EDGAR | |
| BERNADETTE CONNAUGHTON | Director | 1,626 | $168K | View on EDGAR |
HALOZYME THERAPEUTICS, INC. (HALO) had 10 insider filings in the last 90 days, with the most recent on 2026-08-20. The full record for HALO runs to 62 Form 4 filings, the earliest from 2024-10-09. InsiderAlpha tracks every Form 4, Form 144, and 8-K filing in real time.
No insider purchases of HALO were filed in the last 90 days.
27 insider sales of HALO were filed in the last 90 days, totaling $10.75M.
This page tracks HALO Form 4 insider transactions, Form 144 sale notices, and 8-K material event disclosures in one timeline. Annual 10-K and quarterly 10-Q reports live on the company's SEC EDGAR page.
Create a free InsiderAlpha account and press Watch on this page to add HALO to your watchlist. A free account also opens the full scored daily plan with every past day and 3 months of price history. No card is required. Sign up at https://insideralpha.ai/register.
Every Form 4 below links to the original document on SEC EDGAR, so the numbers on this page can be checked against the filing they came from.
Real-time Form 4 alerts, AI-scored daily trade ideas and 10b5-1 plan flags.
